A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-690514 in combination with FOLFIRI [fluorouracil + folinic acid + irinotecan] and FOLFOX [fluorouracil + folinic acid + oxaliplatin] in subjects with advanced metastatic solid tumors

Trial Profile

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-690514 in combination with FOLFIRI [fluorouracil + folinic acid + irinotecan] and FOLFOX [fluorouracil + folinic acid + oxaliplatin] in subjects with advanced metastatic solid tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2010

At a glance

  • Drugs BMS 690514; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 01 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Aug 2009 Planned end date changed from 1 Jul 2009 to 1 Feb 2010 as reported by ClinicalTrials.gov.
    • 20 Feb 2008 Fox Chase Cancer Center now recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top